Skip to main content
. 2018 Feb 12;145(2):111–124. doi: 10.1111/jnc.14290

Figure 5.

Figure 5

Effect of pre‐treatment with S‐(4‐Fluoro‐phenyl)‐{3‐[3‐(4‐fluoro‐phenyl)‐[1,2,4]‐oxadiazol‐5‐yl]‐piperidin‐1‐yl}‐methanone (ADX47273) on glutamate efflux in the mPFC evoked by the NMDA receptor antagonist MK801 (n = 10 rats). (a) Rats received vehicle (p.o.) or ADX47273 (100 mg/kg, p.o.; time bin zero), followed by vehicle (s.c.) or MK801 (0.03, s.c.) 80 min later. Data points represent mean ±1SEM. Repeated‐measures anova. (b) area under the curve (AUC) presented as a histogram, for vehicle or ADX47273 or MK801 or ADX47273 and MK801 treatment (2‐h post‐MK801/vehicle injection). (c) Summary of experimental timeline (BL = baseline).